Patents by Inventor Deborah Rathjen
Deborah Rathjen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210393787Abstract: Disclosed are therapeutic payloads comprising p97 fragments coupled with active agents having blood-brain barrier (BBB) transport activity, including variants and combinations thereof, to facilitate delivery of therapeutic or diagnostic agents across the BBB. The therapeutic payloads can be effective in the treatment of frontotemportal dementia (FTD). Methods of treating frontotemporal dementia (FTD) and pharmaceutical compositions are also disclosed.Type: ApplicationFiled: June 15, 2021Publication date: December 23, 2021Applicant: Bioasis Technologies, Inc.Inventors: Deborah Rathjen, Mei Mei Tian
-
Patent number: 7605233Abstract: The present invention relates to ligands which bind to human tumour necrosis factor alpha (TNF) in a manner such that upon binding of these ligands to TNF the biological activity of TNF is modified. In preferred forms the ligand binds to TNF in a manner such that the induction of fibrin deposition in the tumour and induction of endothelial procoagulant activity of the TNF is inhibited; the binding of TNF to receptors on endothelial cells, tumour regression, cytotoxicity and receptor binding activities of the TNF on tumour cells are unaffected. The ligand is preferably an antibody, F(ab) fragment, single domain antibody (dABs), single chain antibody or a serum binding protein. It is preferred, however, that the ligand is a monoclonal antibody or F(ab) fragment thereof.Type: GrantFiled: June 11, 2007Date of Patent: October 20, 2009Assignee: Arana Therapeutics LimitedInventors: Deborah A. Rathjen, Roger Aston
-
Patent number: 7553641Abstract: The present invention relates to cell lines that produce ligands that bind to human tumor necrosis factor alpha (TNF) in a manner such that upon binding of these ligands to TNF the biological activity of TNF is modified. In preferred forms cell lines produce ligands that bind to TNF in a manner such that the induction of endothelial procoagulant activity of the TNF is inhibited; the binding of TNF to receptors on endothelial cells is inhibited; the induction of fibrin deposition in the tumor and tumor regression activities of the TNF are enhanced; and the cytotoxicity and receptor binding activities of the TNF are unaffected or enhanced on tumor cells. The ligand is preferably an antibody, F(ab) fragment, single domain antibody (dABs), single chain antibody or a serum binding protein. It is preferred, however, that the ligand is a monoclonal antibody or F(ab) fragment thereof.Type: GrantFiled: June 7, 2007Date of Patent: June 30, 2009Assignee: Arana Therapeutics LimitedInventors: Deborah A. Rathjen, Roger Aston
-
Patent number: 7544782Abstract: The present invention relates to ligands which bind to human tumor necrosis factor alpha (TNF) in a manner such that upon binding of these ligands to TNF the biological activity of TNF is modified. In preferred forms the ligand binds to TNF in a manner such that the induction of endothelial procoagulant activity of the TNF is inhibited; the binding of TNF to receptors on endothelial cells is inhibited; the induction of fibrin deposition in the tumor and tumor regression activities of the TNF are enhanced; and the cytotoxicity and receptor binding activities of the TNF are unaffected or enhanced on tumor cells. The ligand is preferably an antibody, F(ab) fragment, single domain antibody (dABs), single chain antibody or a serum binding protein. It is preferred, however, that the ligand is a monoclonal antibody or F(ab) fragment thereof.Type: GrantFiled: February 23, 2006Date of Patent: June 9, 2009Assignee: Arana Therapeutics LimitedInventors: Deborah A. Rathjen, Roger Aston
-
Patent number: 7528237Abstract: The present invention relates to ligands that bind to human tumour necrosis factor alpha (TNF) in a manner such that upon binding of these ligands to TNF the biological activity of TNF is modified. In preferred forms the ligand binds to TNF in a manner such that the induction of endothelial procoagulant activity of the TNF is inhibited; the binding of TNF to receptors on endothelial cells is inhibited; the induction of fibrin deposition in the tumour and tumour regression activities of the TNF are enhanced; and the cytotoxicity and receptor binding activities of the TNF are unaffected or enhanced on tumour cells. The ligand is preferably an antibody, F(ab) fragment, single domain antibody (dABs), single chain antibody or a serum binding protein. It is preferred, however, that the ligand is a monoclonal antibody or F(ab) fragment thereof.Type: GrantFiled: April 19, 2007Date of Patent: May 5, 2009Assignee: Arana Therapeutics LimitedInventors: Deborah A. Rathjen, Roger Aston
-
Patent number: 7517963Abstract: The present invention relates to ligands which bind to human tumor necrosis factor alpha (TNF) in a manner such that upon binding of these ligands to TNF the biological activity of TNF is modified. In preferred forms the ligand binds to TNF in a manner such that the induction of endothelial procoagulant activity of the TNF is inhibited; the binding of TNF to receptors on endothelial cells is inhibited; the induction of fibrin deposition in the tumor and tumor regression activities of the TNF are enhanced; and the cytotoxicity and receptor binding activities of the TNF are unaffected or enhanced on tumor cells. The ligand is preferably an antibody, F(ab) fragment, single domain antibody (dABs), single chain antibody or a serum binding protein. It is preferred, however, that the ligand is a monoclonal antibody or F(ab) fragment thereof.Type: GrantFiled: January 5, 2006Date of Patent: April 14, 2009Assignee: Arana Therapeutics LimitedInventors: Deborah A. Rathjen, Roger Aston
-
Publication number: 20080031956Abstract: A pharmaceutical and/or veterinary formulation comprising about 2-30% (w/w) (on an active basis) of at least one active agent, about 0.5-20.0% (w/w) of a pore-forming agent comprising lecithin and an organic salt, and the balance stearin. Such formulations provide sustained release of the at least one active agent in humans and other animals for periods of 7 days up to about 2 years.Type: ApplicationFiled: March 27, 2007Publication date: February 7, 2008Applicant: Peptech LimitedInventors: Timothy Trigg, John Walsh, Deborah Rathjen
-
Publication number: 20070287177Abstract: The present invention relates to cell lines that produce ligands that bind to human tumour necrosis factor alpha (TNF) in a manner such that upon binding of these ligands to TNF the biological activity of TNF is modified. In preferred forms cell lines produce ligands that bind to TNF in a manner such that the induction of endothelial procoagulant activity of the TNF is inhibited; the binding of TNF to receptors on endothelial cells is inhibited; the induction of fibrin deposition in the tumour and tumour regression activities of the TNF are enhanced; and the cytotoxicity and receptor binding activities of the TNF are unaffected or enhanced on tumour cells. The ligand is preferably an antibody, F(ab) fragment, single domain antibody (dABs), single chain antibody or a serum binding protein. It is preferred, however, that the ligand is a monoclonal antibody or F(ab) fragment thereof.Type: ApplicationFiled: June 7, 2007Publication date: December 13, 2007Inventors: Deborah RATHJEN, Roger Aston
-
Publication number: 20070280932Abstract: The present invention relates to ligands that bind to human tumour necrosis factor alpha (TNF) in a manner such that upon binding of these ligands to TNF the biological activity of TNF is modified. In preferred forms the ligand binds to TNF in a manner such that the induction of endothelial procoagulant activity of the TNF is inhibited; the binding of TNF to receptors on endothelial cells is inhibited; the induction of fibrin deposition in the tumour and tumour regression activities of the TNF are enhanced; and the cytotoxicity and receptor binding activities of the TNF are unaffected or enhanced on tumour cells. The ligand is preferably an antibody, F(ab) fragment, single domain antibody (dABs), single chain antibody or a serum binding protein. It is preferred, however, that the ligand is a monoclonal antibody or F(ab) fragment thereof.Type: ApplicationFiled: April 19, 2007Publication date: December 6, 2007Inventors: Deborah Rathjen, Roger Aston
-
Publication number: 20070077248Abstract: The present invention relates to ligands which bind to human tumour necrosis factor alpha (TNF) in a manner such that upon binding of these ligands to TNF the biological activity of TNF is modified. In preferred forms the ligand binds to TNF in a manner such that the induction of endothelial procoagulant activity of the TNF is inhibited; the binding of TNF to receptors on endothelial cells is inhibited; the induction of fibrin deposition in the tumour and tumour regression activities of the TNF are enhanced; and the cytotoxicity and receptor binding activities of the TNF are unaffected or enhanced on tumour cells. The ligand is preferably an antibody, F(ab) fragment, single domain antibody (dABs), single chain antibody or a serum binding protein. It is preferred, however, that the ligand is a monoclonal antibody or F(ab) fragment thereof.Type: ApplicationFiled: February 23, 2006Publication date: April 5, 2007Applicant: Peptech LimitedInventors: Deborah Rathjen, Roger Aston
-
Publication number: 20070065426Abstract: The present invention relates to ligands which bind to human tumour necrosis factor alpha (TNF) in a manner such that upon binding of these ligands to TNF the biological activity of TNF is modified. In preferred forms the ligand binds to TNF in a manner such that the induction of endothelial procoagulant activity of the TNF is inhibited; the binding of TNF to receptors on endothelial cells is inhibited; the induction of fibrin deposition in the tumour and tumour regression activities of the TNF are enhanced; and the cytotoxicity and receptor binding activities of the TNF are unaffected or enhanced on tumour cells. The ligand is preferably an antibody, F(ab) fragment, single domain antibody (dABs), single chain antibody or a serum binding protein. It is preferred, however, that the ligand is a monoclonal antibody or F(ab) fragment thereof.Type: ApplicationFiled: February 28, 2006Publication date: March 22, 2007Inventors: Deborah Rathjen, Roger Aston
-
Publication number: 20060233802Abstract: The present invention relates to ligands which bind to human tumour necrosis factor alpha (TNF) in a manner such that upon binding of these ligands to TNF the biological activity of TNF is modified. In preferred forms the ligand binds to TNF in a manner such that the induction of endothelial procoagulant activity of the TNF is inhibited; the binding of TNF to receptors on endothelial cells is inhibited; the induction of fibrin deposition in the tumour and tumour regression activities of the TNF are enhanced; and the cytotoxicity and receptor binding activities of the TNF are unaffected or enhanced on tumour cells. The ligand is preferably an antibody, F(ab) fragment, single domain antibody (dABs), single chain antibody or a serum binding protein. It is preferred, however, that the ligand is a monoclonal antibody or F(ab) fragment thereof.Type: ApplicationFiled: June 6, 2006Publication date: October 19, 2006Inventors: Deborah Rathjen, Roger Aston
-
Publication number: 20060204499Abstract: The present invention relates to ligands which bind to human tumour necrosis factor alpha (TNF) in a manner such that upon binding of these ligands to TNF the biological activity of TNF is modified. In preferred forms the ligand binds to TNF in a manner such that the induction of endothelial procoagulant activity of the TNF is inhibited; the binding of TNF to receptors on endothelial cells is inhibited; the induction of fibrin deposition in the tumour and tumour regression activities of the TNF are enhanced; and the cytotoxicity and receptor binding activities of the TNF are unaffected or enhanced on tumour cells. The ligand is preferably an antibody, F(ab) fragment, single domain antibody (dABs), single chain antibody or a serum binding protein. It is preferred, however, that the ligand is a monoclonal antibody or F(ab) fragment thereof.Type: ApplicationFiled: May 8, 2006Publication date: September 14, 2006Applicant: Peptech LimitedInventors: Deborah Rathjen, Roger Aston
-
Publication number: 20060182746Abstract: The present invention relates to ligands which bind to human tumor necrosis factor alpha (TNF) in a manner such that upon binding of these ligands to TNF the biological activity of TNF is modified. In preferred forms the ligand binds to TNF in a manner such that the induction of endothelial procoagulant activity of the TNF is inhibited; the binding of TNF to receptors on endothelial cells is inhibited; the induction of fibrin deposition in the tumor and tumor regression activities of the TNF are enhanced; and the cytotoxicity and receptor binding activities of the TNF are unaffected or enhanced on tumor cells. The ligand is preferably an antibody, F(ab) fragment, single domain antibody (dABs), single chain antibody or a serum binding protein. It is preferred, however, that the ligand is a monoclonal antibody or F(ab) fragment thereof.Type: ApplicationFiled: January 5, 2006Publication date: August 17, 2006Inventors: Deborah Rathjen, Roger Aston
-
Publication number: 20060159677Abstract: Provided are isolated antibodies or fragments thereof which bind a peptide consisting of residues Gly54-Leu55-Tyr56-Leu57-Ile58-Tyr59-Ser60-Gln61-Val62-Leu63-Phe64-Lys65-Gly66-Gln67-Gly68 (peptide 308) of mature human TNF-?. The antibodies and fragments thereof may be used to identify antibodies capable of binding in the region of mature human TNF-? of amino acid resides 54-68. Antibodies or fragments thereof which bind particular regions of mature human TNF-? are shown to elicit particular biological activities dependent upon the particular region wherein binding occurs.Type: ApplicationFiled: March 7, 2006Publication date: July 20, 2006Inventors: Deborah Rathjen, Roger Aston
-
Publication number: 20060140952Abstract: Provided are isolated antibodies or fragments thereof which bind a peptide consisting of residues Ala22-Glu23-Gly24-Gln25-Leu26-Gln27-Trp28-Leu29-Asn30-Arg31-Arg32-Ala33-Asn34-Ala35-Leu36-Leu37-Ala38-Asn39-Gly40 (peptide 307) of mature human TNF-?. The antibodies and fragments thereof may be used to identify antibodies capable of binding in the region of mature human TNF-? of amino acid resides 22-40. Antibodies or fragments thereof which bind particular regions of mature human TNF-? are shown to elicit particular biological activities dependent upon the particular region wherein binding occurs.Type: ApplicationFiled: February 22, 2006Publication date: June 29, 2006Inventors: Deborah Rathjen, Roger Aston
-
Publication number: 20060140951Abstract: Provided are isolated antibodies or fragments thereof which bind a peptide consisting of residues His73-Val74-Leu75-Leu76-Thr77-His78-Thr79-Ile80-Ser81-Arg82-Ile83-Ala84-Val85-Ser86-Tyr87-Gln88-Thr89-Lys90-Val91-Asn92-Leu93-Leu94 (peptide 309) of mature human TNF-?. The antibodies and fragments thereof may be used to identify antibodies capable of binding in the region of mature human TNF-? of amino acid resides 73-94. Antibodies or fragments thereof which bind particular regions of mature human TNF-? are shown to elicit particular biological activities dependent upon the particular region wherein binding occurs.Type: ApplicationFiled: February 22, 2006Publication date: June 29, 2006Inventors: Deborah Rathjen, Roger Aston
-
Publication number: 20050276854Abstract: A pharmaceutical and/or veterinary formulation comprising about 2-30% (w/w) (on an active basis) of at least one active agent, about 0.5-20.0% (w/w) of a pore-forming agent and the balance stearin. Such formulations provide sustained release of the at least one active agent in humans and other animals for periods of 7 days up to about 2 years.Type: ApplicationFiled: January 25, 2005Publication date: December 15, 2005Applicant: Peptech LimitedInventors: Timothy Trigg, John Walsh, Deborah Rathjen
-
Publication number: 20040214993Abstract: The present invention relates to ligands which bind to human tumour necrosis factor alpha (TNF) in a manner such that upon binding of these ligands to TNF the biological activity of TNF is modified. In preferred forms the ligand binds to TNF in a manner such that the induction of endothelial procoagulant activity of the TNF is inhibited; the binding of TNF to receptors on endothelial cells is inhibited; the induction of fibrin deposition in the tumour and tumour regression activities of the TNF are enhanced; and-the cytotoxicity and receptor binding activities of the TNF are unaffected or enhanced on tumour cells. The ligand is preferably an antibody, F(ab) fragment, single domain antibody (dABs) single chain antibody or a serum binding protein. It is preferred, however, that the ligand is a monoclonal antibody or F(ab) fragment thereof.Type: ApplicationFiled: October 3, 2002Publication date: October 28, 2004Inventors: Deborah RATHJEN, Roger ASTON
-
Publication number: 20030171555Abstract: The present invention relates to ligands which bind to human tumour necrosis factor alpha (TNF) in a manner such that upon binding of these ligands to TNF the biological activity of TNF is modified. In preferred forms the ligand binds to TNF in a manner such that the induction of endothelial procoagulant activity of the TNF is inhibited; the binding of TNF to receptors on endothelial cells is inhibited; the induction of fibrin deposition in the tumour and tumour regression activities of the TNF are enhanced; and the cytotoxicity and receptor binding activities of the TNF are unaffected or enhanced on tumour cells. The ligand is preferably an antibody, F(ab) fragment, single domain antibody (dABs) single chain antibody or a serum binding protein. It is preferred, however, that the ligand is a monoclonal antibody or F(ab) fragment thereof.Type: ApplicationFiled: January 15, 2003Publication date: September 11, 2003Inventors: Deborah A. Rathjen, Roger Aston